Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2014

View Archived Issues

Merrimack Pharmaceuticals begins phase II trial of MM-302 in HER2-positive breast cancer

NIPER reports novel PON 1 enzymes

Forma Therapeutics and Paradigm enter into molecular profiling collaboration

Characterization of potential disease-causing mutations in tRNA genes

AstraZeneca reports topline results from pivotal studies of lesinurad for gout

Seattle Genetics begins phase I study of SGN-CD70A

Novogen receives funding to begin studies in muscular dystrophy

Advanced Proteome Therapeutics updates progress of cancer program

Pfizer presents DGAT2 inhibitors with activity in preclinical models of metabolic disease

23andMe and Pfizer collaborate to investigate genetics of inflammatory bowel disease

Flex Pharma reports data for proprietary product for preventing muscle cramps

Novel small-molecule GK-GKRP inhibitors with the ability to lower blood glucose levels in vivo

First-in-class APOBEC3 enzyme inhibitors identified as potential oncolytic candidates

Merck & Co. reports glucokinase activators as diabetes treatment candidates

Novel ACC-beta inhibitors described by Boehringer Ingelheim

New vaccines for Francisella tularensis infection

Researchers at Janssen disclose novel agents for RSV infection

Roche synthesizes new LMP7 inhibitors

FDA approves Belsomra for insomnia

Insys Therapeutics submits NDA for new oral formulation of dronabinol

RedHill Biopharma gains option for RP-101 from RESprotect

Lithera changes name to Neothetics

Phase II trial to test safety and efficacy of fexinidazole in Chagas disease

Sirona subsidiary receives funding for anti-aging project

Rigel's R-348 misses endpoints in keratoconjunctivitis sicca trial

Medicure reports data from phase II trial of Tardoxal in tardive dyskinesia

Allergan acquires lidocaine for interstitial cystitis/bladder pain syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.